Animal Sedative Market to Grow with a CAGR of 4.30% through 2028

Rising demand for veterinary care and advancements in veterinary medicine are expected to drive the Global Animal Sedative Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Animal Sedative Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Animal Sedative Market stood at USD 121.11 million in 2022 and is anticipated to grow with a CAGR of 4.30% in the forecast period, 2024-2028. This can be attributed to growing veterinary tourism. Some countries have become popular destinations for veterinary tourism, attracting pet owners from around the world seeking high-quality and cost-effective veterinary care. As this trend continues to grow, it has a ripple effect on the global animal sedative market, as these facilities require a steady supply of sedatives for their international clientele.

Furthermore, pain management for animals is gaining prominence. Sedatives are not only used to calm animals but also to provide pain relief during procedures. Sedatives that effectively manage pain while maintaining safety are increasingly sought after.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Animal Sedative Market.”

The animal sedative market experienced significant disruption during the initial wave of the COVID-19 pandemic as governments worldwide implemented containment measures such as lockdowns and social distancing, leading to a substantial reduction in veterinary hospital and pharmacy operations. For instance, a December 2022 study by Faunalytics revealed that to prevent disease transmission, approximately 70% of clinics in the United States and Canada temporarily closed to the public, resulting in animals attending appointments without their owners. These clinics also faced critical shortages, with 82% experiencing deficits in pet food, medications, or personal protective equipment, and 56% running out of at least one of these essential items. Vaccines were particularly scarce. However, as pandemic restrictions eased, the animal sedative market is poised for growth in the coming years, driven by an increase in animal surgeries and the introduction of new veterinary sedative products.

Furthermore, factors contributing to the expansion of the animal sedatives market include the rising incidence of zoonotic diseases associated with surgical procedures, a growing pet population, and increased investment in veterinary product development. For example, according to the 2021-2022 National Pet Owners Survey by the American Pet Products Association (APPA), approximately 70% of U.S. households, equivalent to about 90.5 million families, own a pet, reflecting an increased focus on pet health and a likelihood of increased pet healthcare expenditure.

Research studies and developments aimed at comparing the efficacy of various veterinary sedative products are expected to fuel market growth. For instance, a December 2022 article in Frontiers reported that a single dose of romifidine or a combination of romifidine and lidocaine administered epidurally induced mild to moderate drowsiness and complete pain relief in the perineal and inguinal regions of donkeys. This technique offers convenience for providing analgesia as it is simple, cost-effective, and does not require specialized equipment. Such advancements in veterinary sedative utilization are projected to drive market growth in the forecast period.

Additionally, strategic partnerships and product launches by key players are expected to contribute to market expansion. In September 2022, Zoetis acquired Jurox, a privately held animal health company specializing in a wide range of veterinary medicines for livestock and companion animals. This acquisition provided Zoetis with a valuable animal health portfolio, including the anesthetic product Alfaxan, along with strong R&D and manufacturing capabilities, fostering global expansion.

In summary, the animal sedative market is expected to experience significant growth due to the rising animal population, increased strategic activities by key industry players, and ongoing research demonstrating sedative efficacy. However, challenges such as emerging adverse effects of sedative drugs and stringent government regulations are anticipated to temper market growth in the forecast period.

The Global Animal Sedative Market is segmented into type, route of administration, regional distribution, and company.

Based on its type, Acepromazine is poised to dominate the Global Animal Sedative Market in 2022 and maintain its stronghold throughout the forecast years for several compelling reasons. Firstly, Acepromazine boasts a long-standing reputation for its efficacy and safety in sedating a wide range of animals, from small pets to large livestock, making it a trusted choice among veterinarians and animal caregivers worldwide. Additionally, the drug's consistent quality and reliable results have earned it the trust of the global veterinary community. Furthermore, Acepromazine's cost-effectiveness compared to alternative sedatives positions it as an attractive option, particularly in regions where cost considerations play a significant role in decision-making. As research and development efforts continue to refine its formulation and delivery methods, Acepromazine is well-positioned to meet evolving market demands, ensuring its dominance in the Global Animal Sedative Market for years to come.

Based on route of administration, the Parenteral route of administration is poised to dominate the Global Animal Sedative Market in 2022, while oral alternatives are expected to experience substantial growth during the forecast years. Parenteral sedatives, delivered through injections or intravenous means, have long been favored for their immediate and precise effects, making them the preferred choice for critical or emergency situations in veterinary practice. However, oral sedatives are anticipated to grow in popularity due to their ease of administration, reduced stress on animals, and increased convenience for caregivers, particularly for routine procedures and home care. This anticipated growth in the oral segment reflects a shift towards more humane and accessible sedation options for animals, while Parenteral sedatives will continue to hold a strong position in scenarios where rapid sedation is imperative. As the market evolves to accommodate diverse needs, both Parenteral and oral segments are expected to coexist and collectively drive the expansion of the Global Animal Sedative Market.

Major companies operating in Global Animal Sedative Market are:

• Zoetis Inc
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• Elanco Animal Health Inc
• Virbac SA
• Dechra Pharmaceuticals PLC
• Orion Corporation
• Vetoquinol SA

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The global animal sedative market is poised for significant transformation in the coming years. The upcoming trends reflect the changing landscape of animal care, driven by the evolving expectations of pet owners, veterinarians, and regulators. As these trends continue to shape the industry, stakeholders in the animal sedative market must remain agile and responsive to meet the evolving needs of animals and their caregivers,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Animal Sedative Market By Type (Acepromazine, Butorphanol, Detomidine, Romifidine, Xylazine), By Route of Administration (Oral, Parenteral), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Animal Sedative Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Animal Sedative Market.

Contact

Mr. Ken Mathews

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]

Website: www.techsciresearch.com